In this article by the Manufacturing Chemist, Dr Andy Lewis, Chief Scientific Officer at Quotient Sciences reviews the trends driving the adoption of oral peptide products and considers the strategies to overcome the development challenges associated with effective delivery.
The article explores the future of GLP-1s and oral peptides, as advancements in drug delivery are transforming treatment options for patients.
Recent innovations are enabling the development of oral peptide products, which offer a more convenient and non-invasive alternative.
Given that approximately 90% of drugs fail during the clinical trial phase, developing strategies to address this is imperative.
Continue reading the article on Manufacturing Chemist.